Latest posts in

Thought Leadership

GLP-1s are No Laughing Matter
GLP-1s are No Laughing Matter

The rise of GLP-1s as an option to aid weight loss across America, fueled by celebrities on social media, is not something we should take lightly.

Read
Prescription Discount Cards, Drug Prices, and Data
Prescription Discount Cards, Drug Prices, and Data

Healthcare consumers are using prescription discount cards more frequently; Capital Rx explains who needs them and how they work.

Read
Why Now Is the Time for Health Plans to Take Control of Pharmacy Benefits
Why Now Is the Time for Health Plans to Take Control of Pharmacy Benefits

Capital Rx's Philip Vecchiolli explains how new technology provides health plans with greater transparency and an improved member experience.

Read
What You Should be Doing Now to Optimize Your Pharmacy Benefit for 2023
What You Should be Doing Now to Optimize Your Pharmacy Benefit for 2023

14 suggestions for employers and other plan sponsors to optimize pharmacy benefits spend from Capital Rx's leadership team.

Read
Fixing price instability can improve access to affordable prescription drugs
Fixing price instability can improve access to affordable prescription drugs

Capital Rx's Matthew Gibbs, PharmD, suggests using a more stable drug price index (NADAC) to improve access to medication in the US.

Read
Our Single-Ledger Model™ - Pharma Revenue Explained
Our Single-Ledger Model™ - Pharma Revenue Explained

Rebates from pharmaceutical manufacturers are not the only source of revenue PBMs receive from pharma...

Read
Self-funded plans ignore the Consolidated Appropriations Act at their peril
Self-funded plans ignore the Consolidated Appropriations Act at their peril

The Consolidated Appropriations Act includes several new fiduciary responsibilities that plan sponsors should keep in mind.

Read
Highlights from HBN ‘22 – Solving the Drug Spend Crisis: What Employers Can (Should) Do
Highlights from HBN ‘22 – Solving the Drug Spend Crisis: What Employers Can (Should) Do

Highlights from Health Benefits Nation '22 and the Solving the Drug Spend Crisis: What Employers Can (Should) Do panel discussion...

Read